Health Care • Biotechnology: Pharmaceutical Preparations
$23.47 ▲ +0.14
(+0.60%)
MKT CAP: $921.0M • VOL: 388.8K
52W L $10 52W H $37
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
ANRO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$66.4M | -$68.6M | -$37.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$63.2M | -$61.4M | -$36.3M |
| EBITDA (Normalized) | -$66.3M | -$67.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$51.8M | -$47.4M | -$33.4M |
| Capital Expenditures (CapEx) | $24.0K | $2.1M | — |
| Free Cash Flow (FCF) | -$51.8M | -$49.5M | -$33.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $176.5M | $168.2M | — |
| Total Debt (Short + Long Term) | $16.2M | $10.3M | — |
| Total Stockholders' Equity | $151.1M | $151.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANRO.